Mizuho reiterated their buy rating on shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) in a report issued on Thursday morning. Mizuho currently has a $24.00 price objective on the biopharmaceutical company’s stock.

AKBA has been the topic of a number of other reports. Royal Bank Of Canada reissued a hold rating and issued a $17.00 price objective on shares of Akebia Therapeutics in a research note on Thursday, November 2nd. Zacks Investment Research raised shares of Akebia Therapeutics from a hold rating to a buy rating and set a $16.00 price objective on the stock in a research note on Monday, August 14th. BidaskClub cut shares of Akebia Therapeutics from a hold rating to a sell rating in a research note on Wednesday, July 19th. ValuEngine raised shares of Akebia Therapeutics from a sell rating to a hold rating in a research note on Friday, September 1st. Finally, HC Wainwright reissued a buy rating and issued a $24.00 price objective on shares of Akebia Therapeutics in a research note on Wednesday, August 9th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $20.63.

Shares of Akebia Therapeutics (NASDAQ:AKBA) traded up $0.39 on Thursday, hitting $15.49. 674,287 shares of the stock were exchanged, compared to its average volume of 515,648. Akebia Therapeutics has a 1-year low of $7.78 and a 1-year high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.07. The business had revenue of $41.28 million during the quarter, compared to the consensus estimate of $34.00 million. Akebia Therapeutics had a negative net margin of 137.80% and a negative return on equity of 244.78%. analysts forecast that Akebia Therapeutics will post -3.03 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/akebia-therapeutics-inc-akba-receives-buy-rating-from-mizuho/1694453.html.

In other Akebia Therapeutics news, SVP Michel Dahan sold 5,000 shares of the firm’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $19.30, for a total transaction of $96,500.00. Following the sale, the senior vice president now directly owns 97,224 shares of the company’s stock, valued at approximately $1,876,423.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 12,586 shares of company stock worth $222,289 over the last ninety days. 7.95% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in AKBA. American International Group Inc. boosted its stake in shares of Akebia Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 22,121 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 1,460 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Akebia Therapeutics by 17.4% during the 1st quarter. Wellington Management Group LLP now owns 152,020 shares of the biopharmaceutical company’s stock worth $1,399,000 after purchasing an additional 22,520 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Akebia Therapeutics by 8.8% during the 1st quarter. Vanguard Group Inc. now owns 1,301,880 shares of the biopharmaceutical company’s stock worth $11,977,000 after purchasing an additional 105,645 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Akebia Therapeutics by 4.7% during the 1st quarter. Geode Capital Management LLC now owns 330,096 shares of the biopharmaceutical company’s stock worth $3,036,000 after purchasing an additional 14,959 shares during the last quarter. Finally, UBS Group AG boosted its stake in shares of Akebia Therapeutics by 79.0% during the 1st quarter. UBS Group AG now owns 151,646 shares of the biopharmaceutical company’s stock worth $1,395,000 after purchasing an additional 66,948 shares during the last quarter. 58.25% of the stock is currently owned by institutional investors.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.